{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:28:40Z","timestamp":1793921320802,"version":"4.8.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We present the preclinical rationale and clinical data from a phase 1b trial investigating the STING agonist dazostinag plus pembrolizumab following hypofractionated radiotherapy (RT) in patients with advanced non\u2013small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous cell carcinoma of the head and neck (SCCHN) whose disease had progressed on prior checkpoint inhibitors (CPI; NCT04879849).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Eligible patients received radiation (8 Gy \u00d7 3 fractions) followed (\u226540 hours) by pembrolizumab 200 mg every 3 weeks and dazostinag in escalating doses (0.2\u20135.0 mg). Primary endpoints were safety and tolerability. Secondary endpoints included preliminary antitumor activity in irradiated and nonirradiated lesions, pharmacokinetic analyses, and pharmacodynamic analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Preclinical studies demonstrated tumor control and enhanced intratumoral immune activation in mice treated with dazostinag plus radiation. Thirty-four patients (NSCLC: 15, SCCHN: 10, and TNBC: 9) with a median number of six prior treatments were enrolled. Thirty-three (97.1%) patients reported treatment-emergent adverse events (TEAE), none were dose-limiting toxicities; the most common were fatigue (52.9%), constipation (26.5%), and cough (20.6%). Dazostinag-related TEAEs occurred in 17 patients (50.0%); the most common were fatigue (26.5%), chills (8.8%), diarrhea, arthralgia, and myalgia (5.9% each). Antitumor activity, per RECIST v.1.1, was confirmed in two (7.1%) patients (one complete response and one partial response). Pharmacodynamic analyses indicated activation of STING and IFN\u03b3 pathways across multiple dose levels and induced immune responses, consistent with preclinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dazostinag, combined with pembrolizumab after RT, was well tolerated and demonstrated clinical activity in some patients with advanced\/metastatic tumors whose disease had progressed on CPIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Dazostinag, an intravenous STING agonist, combined with radiation, demonstrated tumor control and enhanced intratumoral immune activation, preclinically. In phase 1b, dazostinag plus pembrolizumab following RT had a manageable safety profile and provided clinical benefit for some heavily pretreated patients with advanced\/metastatic solid tumors whose disease had progressed on CPIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0566","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:54:36Z","timestamp":1764183276000},"page":"2249-2263","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-7989","authenticated-orcid":false,"given":"Benjamin T.","family":"Cooper","sequence":"first","affiliation":[{"name":"1Radiation Oncology, NYU Langone School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-298X","authenticated-orcid":false,"given":"Wade T.","family":"Iams","sequence":"additional","affiliation":[{"name":"2Oncology, Vanderbilt University, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-4628","authenticated-orcid":false,"given":"David B.","family":"Page","sequence":"additional","affiliation":[{"name":"3Medicine, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7440-8939","authenticated-orcid":false,"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"4Medical Oncology, Cedars Sinai Medical Center, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-0498","authenticated-orcid":false,"given":"Naamit K.","family":"Gerber","sequence":"additional","affiliation":[{"name":"1Radiation Oncology, NYU Langone School of Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J.","family":"Luke","sequence":"additional","affiliation":[{"name":"5Hematology\/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-7318","authenticated-orcid":false,"given":"John P.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"6Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-1882","authenticated-orcid":false,"given":"Richard C.","family":"Gregory","sequence":"additional","affiliation":[{"name":"7Oncology Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-235X","authenticated-orcid":false,"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Laura & Issac Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-8643","authenticated-orcid":false,"given":"Jiehui","family":"Deng","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Laura & Issac Perlmutter Cancer Center, NYU Langone Health, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-7086","authenticated-orcid":false,"given":"Samanthi A.","family":"Perera","sequence":"additional","affiliation":[{"name":"7Oncology Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-465X","authenticated-orcid":false,"given":"Kai","family":"Ding","sequence":"additional","affiliation":[{"name":"7Oncology Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9672-0443","authenticated-orcid":false,"given":"Emily R.","family":"Roberts","sequence":"additional","affiliation":[{"name":"9Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-2005","authenticated-orcid":false,"given":"Allison","family":"Berger","sequence":"additional","affiliation":[{"name":"7Oncology Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3313-2615","authenticated-orcid":false,"given":"Camilla L.","family":"Christensen","sequence":"additional","affiliation":[{"name":"7Oncology Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3229-527X","authenticated-orcid":false,"given":"Erica Xin","family":"Tong","sequence":"additional","affiliation":[{"name":"10Statistical and Quantitative Sciences, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9329-2814","authenticated-orcid":false,"given":"Angel E.","family":"Maldonado L\u00f3pez","sequence":"additional","affiliation":[{"name":"9Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9132-1322","authenticated-orcid":false,"given":"Vicky A.","family":"Appleman","sequence":"additional","affiliation":[{"name":"9Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6261-2289","authenticated-orcid":false,"given":"E. Jane","family":"Leonard","sequence":"additional","affiliation":[{"name":"11Research and Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-3719","authenticated-orcid":false,"given":"Alexander","family":"Parent","sequence":"additional","affiliation":[{"name":"11Research and Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-518X","authenticated-orcid":false,"given":"Yu-Chung","family":"Huang","sequence":"additional","affiliation":[{"name":"11Research and Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7197-3465","authenticated-orcid":false,"given":"Camden","family":"Bay","sequence":"additional","affiliation":[{"name":"12Oncology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9658-5717","authenticated-orcid":false,"given":"Cong","family":"Li","sequence":"additional","affiliation":[{"name":"10Statistical and Quantitative Sciences, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9156-4423","authenticated-orcid":false,"given":"Neil","family":"Lineberry","sequence":"additional","affiliation":[{"name":"12Oncology, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8469-2509","authenticated-orcid":false,"given":"Jeffrey","family":"Raizer","sequence":"additional","affiliation":[{"name":"11Research and Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8902-7661","authenticated-orcid":false,"given":"Daniel J.","family":"Olson","sequence":"additional","affiliation":[{"name":"13Medicine, University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8851-7108","authenticated-orcid":false,"given":"Steven J.","family":"Chmura","sequence":"additional","affiliation":[{"name":"14Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2025123100362469000_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"2025123100362469000_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","article-title":"Hallmarks of resistance to immune-checkpoint inhibitors","volume":"10","author":"Karasarides","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025123100362469000_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"2025123100362469000_bib4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","article-title":"Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities","volume":"129","author":"Wang","year":"2023","journal-title":"Br J Cancer"},{"key":"2025123100362469000_bib5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.semcancer.2022.02.019","article-title":"Resistance to immune checkpoint blockade: mechanisms, counter-acting approaches, and future directions","volume":"86","author":"Haddad","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2025123100362469000_bib6","doi-asserted-by":"crossref","first-page":"e004863","DOI":"10.1136\/jitc-2022-004863","article-title":"Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects","volume":"10","author":"Peters","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"Suppl 15","key":"2025123100362469000_bib7","doi-asserted-by":"crossref","first-page":"TPS2670","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2670","article-title":"A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors","volume":"39","author":"Falchook","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025123100362469000_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025123100362469000_bib9","doi-asserted-by":"crossref","first-page":"e000695","DOI":"10.1136\/jitc-2020-000695","article-title":"Lifting the innate immune barriers to antitumor immunity","volume":"8","author":"Rothlin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025123100362469000_bib10","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.3390\/ijms21218151","article-title":"Immunomodulatory effects of radiotherapy","volume":"21","author":"Kumari","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025123100362469000_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/stem.3391","article-title":"Radiotherapy and the immune system: more than just immune suppression","volume":"39","author":"R\u00fcckert","year":"2021","journal-title":"Stem Cells"},{"key":"2025123100362469000_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40364-024-00628-3","article-title":"Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark Res"},{"key":"2025123100362469000_bib13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","article-title":"Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment","volume":"25","author":"Sato","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2025123100362469000_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025123100362469000_bib15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"2025123100362469000_bib16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025123100362469000_bib17","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025123100362469000_bib18","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025123100362469000_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"2025123100362469000_bib20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"2025123100362469000_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025123100362469000_bib22","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025123100362469000_bib23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"2025123100362469000_bib24","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025123100362469000_bib25","doi-asserted-by":"crossref","first-page":"e46935","DOI":"10.15252\/embr.201846935","article-title":"Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches","volume":"19","author":"Khoo","year":"2018","journal-title":"EMBO Rep"},{"key":"2025123100362469000_bib26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/cncr.34683","article-title":"Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer","volume":"129","author":"Villaruz","year":"2023","journal-title":"Cancer"},{"key":"2025123100362469000_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/2767-9764.CRC-21-0161","article-title":"TAK-676: a novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies","volume":"2","author":"Carideo Cunniff","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2025123100362469000_bib28","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/acs.jmedchem.1c00374","article-title":"Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route","volume":"64","author":"Vyskocil","year":"2021","journal-title":"J Med Chem"},{"issue":"Suppl 2","key":"2025123100362469000_bib29","doi-asserted-by":"crossref","first-page":"S625","DOI":"10.1016\/j.annonc.2023.09.2168","article-title":"1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: preliminary safety, PK\/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)","volume":"34","author":"Olszanski","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"2025123100362469000_bib30","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2024.08.1055","article-title":"996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced\/metastatic solid tumors: data from phase I dose escalation","volume":"35","author":"Luke","year":"2024","journal-title":"Ann Oncol"},{"key":"2025123100362469000_bib31","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.19.02985","article-title":"Response criteria for intratumoral immunotherapy in solid tumors: itRECIST","volume":"38","author":"Goldmacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025123100362469000_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21105\/joss.00861","article-title":"UMAP: uniform manifold approximation and projection","volume":"3","author":"McInnes","year":"2018","journal-title":"J Open Source Softw"},{"key":"2025123100362469000_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2025123100362469000_bib34","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1158\/1538-7445.AM2025-7143","article-title":"Abstract 7143: development of a peripheral dazostinag (TAK-676) activation RNASeq signature to evaluate STING pharmacodynamic modulation in human solid tumor clinical trials","volume":"85","author":"Ding","year":"2025","journal-title":"Cancer Res"},{"key":"2025123100362469000_bib35","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025123100362469000_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2025123100362469000_bib37","doi-asserted-by":"crossref","first-page":"20190955","DOI":"10.1259\/bjr.20190955","article-title":"Reduced radiation-induced toxicity by using proton therapy for the treatment of oropharyngeal cancer","volume":"93","author":"Meijer","year":"2020","journal-title":"Br J Radiol"},{"key":"2025123100362469000_bib38","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1188\/14.CJON.E37-E44","article-title":"Predicting radiotherapy-related clinical toxicities in cancer: a literature review","volume":"18","author":"O\u2019Gorman","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"2025123100362469000_bib39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbi.2024.02.003","article-title":"Type I interferons, inflammation, and fatigue in a longitudinal RNA study of women with breast cancer","volume":"118","author":"Bower","year":"2024","journal-title":"Brain Behav Immun"},{"key":"2025123100362469000_bib40","doi-asserted-by":"crossref","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2025123100362469000_bib41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025123100362469000_bib42","doi-asserted-by":"crossref","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front Immunol"},{"key":"2025123100362469000_bib43","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.3390\/ijms19123855","article-title":"Radiation-induced reactions in the liver - modulation of radiation effects by lifestyle-related factors","volume":"19","author":"Nakajima","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025123100362469000_bib44","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.3390\/cancers13205174","article-title":"The current landscape of NKT cell immunotherapy and the hills ahead","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025123100362469000_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","article-title":"The development of STING agonists and emerging results as a cancer immunotherapy","volume":"25","author":"Hines","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 16","key":"2025123100362469000_bib46","doi-asserted-by":"crossref","first-page":"TPS2693","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2693","article-title":"A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas","volume":"42","author":"Foldi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"2025123100362469000_bib47","doi-asserted-by":"crossref","first-page":"TPS3162","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3162","article-title":"A phase Ia\/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors","volume":"38","author":"Janku","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025123100362469000_bib48","doi-asserted-by":"crossref","first-page":"e010511","DOI":"10.1136\/jitc-2024-010511","article-title":"Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors","volume":"13","author":"Luke","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2025123100362469000_bib49","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0566\/3703584\/crc-25-0566.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2249\/3719851\/crc-25-0566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2249\/3719851\/crc-25-0566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T05:37:02Z","timestamp":1767159422000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/12\/2249\/771245\/Phase-1b-Study-of-Dazostinag-plus-Pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0566","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30977591","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977594","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977612","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977645","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977624","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977636","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977603","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977615","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977597","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977630","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977621","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977600","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977633","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977609","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977627","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977606","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30977618","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8225213","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}